Effects of Nateglinide and Glibenclamide on Prothrombotic Factors in Naïve Type 2 Diabetic Patients Treated with Metformin: A 1-Year, Double-Blind, Randomized Clinical Trial
スポンサーリンク
概要
- 論文の詳細を見る
Objective To evaluate the effect on coagulation and fibrinolysis parameters and on non-conventional cardiovascular risk factors of metformin plus nateglinide or glibenclamide in naïve type 2 diabetes patients. Patients and Methods A total of 248 type 2 diabetic patients were enrolled and randomly assigned to receive nateglinide or glibenclamide, and metformin for 12 months. We assessed body mass index (BMI), glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), postprandial plasma glucose (PPG), fasting plasma insulin (FPI), postprandial plasma insulin (PPI), homeostasis model assessment index (HOMA index), lipid profile with lipoprotein (a) [Lp(a)], fibrinogen (Fg), plasminogen activator inhibitor-1 (PAI-1), tissue plasminogen activator (t-PA), homocysteine (Hcy), systolic blood pressure (SBP), diastolic blood pressure (DBP). Results After 9 months of treatment, both tested drug combinations were similarly associated with a significant reduction in FPG (nateglinide, -17.2%; glibenclamide, -16.9%, both p<0.05) compared to the baseline, while HbA1c (-17.3%, p<0.05) and PPG (-15.2%, p<0.05) significantly decreased only in the nateglinide group. After one year of treatment, compared to the baseline the nateglinide group showed a significant reduction in HbA1c (-21%, p<0.01), FPG (-20.7%), p<0.01, PPG (-21.5%, p<0.05), HOMA index (-25.4%, p<0.05); the glibenclamide group, showed a significant reduction in HbA1c (-11%, p<0.05), FPG (-23.2%, p<0.05), PPG (-11.2%, p<0.05), and HOMA index (-23.9%, p<0.05) but to a minor extent. Moreover, the HbA1c difference value from baseline observed in the nateglinide-treated group was significantly higher than that observed in the glibenclamide group. Therefore the nateglinide-treated patients showed a significant reduction in some prothrombotic parameters (PAI-1=-19%, Lp(a)=-31%, and Hcy=-32.3%, all p<0.05), whereas the glibenclamide-treated patients did not. Conclusion Nateglinide appears to improve glycemic control as well as the levels of some prothrombotic parameters compared to glibenclamide when administered in combination with metformin.
著者
-
Ferrari Ilaria
Department Of Internal Medicine And Therapeutics University Of Pavia
-
Salvadeo Sibilla
Department Of Internal Medicine And Therapeutics University Of Pavia
-
Gravina Alessia
Department Of Internal Medicine And Therapeutics University Of Pavia
-
FOGARI Elena
Department of Internal Medicine and Therapeutic, Clinica Medica II, IRCCS Policlinico S. Matteo, Uni
-
Derosa Giuseppe
Department Of Internal Medicine And Therapeutics Centro Ipertensione E Fisiopatologia Cardiovascolar
-
CICERO ARRIGO
"G. Descovich" Atherosclerosis Study Center, Department of Internal Medicine, Aging and Kidney disea
-
Fogari Elena
Department of Internal Medicine and Therapeutics, University of Pavia
-
Cicero Arrigo
"G. Descovich" Atherosclerosis Study Center, "D. Campanacci" Clinical Medicine and Applied Biotechnology Department, University of Bologna
関連論文
- Pioglitazone Metabolic Effect in Metformin-Intolerant Obese Patients Treated with Sibutramine
- Candesartan effect on inflammation in hypertension
- Effects of Insulin Therapy with Continuous Subcutaneous Insulin Infusion (CSII) in Diabetic Patients : Comparison with Multi-daily Insulin Injections Therapy (MDI)
- Effect of body weight loss and normalization on blood pressure in overweight non-obese patients with stage 1 hypertension
- Serum Testosterone Levels and Arterial Blood Pressure in the Elderly
- Blood Pressure Control and Inflammatory Markers in Type 2 Diabetic Patients Treated with Pioglitazone or Rosiglitazone and Metformin
- Telmisartan and Irbesartan Therapy in Type 2 Diabetic Patients Treated with Rosiglitazone : Effects on Insulin-Resistance, Leptin and Tumor Necrosis Factor-α
- Thiazolidinedione Effects on Blood Pressure in Diabetic Patients with Metabolic Syndrome Treated with Glimepiride
- Effects of Manidipine/Delapril versus Olmesartan/Hydrochlorothiazide Combination Therapy in Elderly Hypertensive Patients with Type 2 Diabetes Mellitus
- Prevalence of Primary Aldosteronism among Unselected Hypertensive Patients : A Prospective Study Based on the Use of an Aldosterone/Renin Ratio above 25 as a Screening Test
- Comparison of the Effects of Valsartan and Felodipine on Plasma Leptin and Insulin Sensitivity in Hypertensive Obese Patients
- Effects of Telmisartan Compared with Eprosartan on Blood Pressure Control, Glucose Metabolism and Lipid Profile in Hypertensive, Type 2 Diabetic Patients : a Randomized, Double-Blind, Placebo-Controlled 12-Month Study
- Sibutramine and L-Carnitine Compared to Sibutramine Alone on Insulin Resistance in Diabetic Patients
- Different actions of losartan and ramipril on adipose tissue activity and vascular remodeling biomarkers in hypertensive patients
- Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients
- Effect of Delapril/Manidipine vs Olmesartan/ Hydrochlorothiazide Combination on Insulin Sensitivity and Fibrinogen in Obese Hypertensive Patients
- Effects of Nateglinide and Glibenclamide on Prothrombotic Factors in Naïve Type 2 Diabetic Patients Treated with Metformin: A 1-Year, Double-Blind, Randomized Clinical Trial
- Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients
- Role of angiotensin II in plasma PAI-1 changes induced by imidapril or candesartan in hypertensive patients with metabolic syndrome
- Glyco-metabolic profile among type 2 diabetic patients with erectile dysfunction
- Effect of Valsartan Addition to Amlodipine on Insulin Sensitivity in Overweight-Obese Hypertensive Patients
- Fibrinolysis and insulin sensitivity in imidapril and candesartan (FISIC study) recipients with hypertension